



PTO/SB/30 (10-01)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

REQUEST FOR CONTINUED EXAMINATION (RCE) TRANSMITTAL Address to: Commissioner for Patents Box RCE Washington, DC 20231	Application Number	09/661,693
	Filing Date	September 14, 2000
	First Named Inventor	S. Indiran Pather, Ph.d.
	Group Art Unit	1616
	Examiner Name	Dewitty
	Attorney Docket No.	CIMA 3.0-030 CONT CONT

This is a Request for Continued Examination (RCE) under 37 CFR 1.114 of the above-identified application.

Request for Continued Examination (RCE) practice under 37 CFR 1.114 does not apply to any utility or plant application filed prior to June 8, 1995, or to any design application. See Instruction Sheet for RCEs (not to be submitted to the USPTO) on page 2.

1. **Submission required under 37 CFR 1.114**

a. ☐ Previously submitted

i. ☐ Consider the amendment(s)/reply under 37 CFR 1.116 previously filed on _____
(Any unentered amendment(s) referred to above will be entered).

ii. ☐ Consider the arguments in the Appeal Brief or Reply Brief previously filed on _____

iii. ☐ Other _____

b. ☒ Enclosed

i. ☒ Amendment/Reply

ii. ☐ Affidavit(s)/Declaration(s)

iii. ☐ Information Disclosure Statement (IDS)

iv. ☐ Other _____

2. **Miscellaneous**

a. ☐ Suspension of action on the above-identified application is requested under 37 CFR 1.103(c) for a period of _____ months. (Period of suspension shall not exceed 3 months; Fee under 37 CFR 1.17(i) required)

b. ☐ Other _____

3. **Fees** The RCE fee under 37 CFR 1.17 (e) is required by 37 CFR 1.114 when the RCE is filed.

a. ☒ The Director is hereby authorized to charge the following fees, or credit any overpayments, to Deposit Account No. 12-1095

i. ☒ RCE fee required under 37 CFR 1.17(e)

ii. ☐ Extension of time fee (37 CFR 1.136 and 1.17)

iii. ☐ Other _____

b. ☐ Check in the amount of \$ _____ enclosed

c. ☐ Payment by credit card (Form PTO-2038 enclosed)

RECEIVED

OCT 18 2002

TECH CENTER 1600/2900

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT REQUIRED			
Name (Print/Type)	Michael H. Teschner	Registration No. (Attorney/Agent)	32,862
Signature		Date	October 10, 2002

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: Box RCE, Commissioner for Patents, Washington, DC 20231, on the date shown below.

Dated: October 10, 2002

Signature: (Michael H. Teschner)


10/16/2002 SDENBOB1 00000170 121095 09661693
02 FC:1801 740.00 CH

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: Box RCE, Commissioner for Patents, Washington, DC 20231, on the date shown below.

Dated: October 10, 2002

Signature: (Michael H. Teschner)

#17D
10/22/02



Docket No.: CIMA 3.0-030 CONT CONT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Pather et al.

Application No.: 09/661,693

Group Art Unit: 1616

Filed: September 14, 2000

Examiner: Dewitty

For: SUBLINGUAL BUCCAL EFFERVESCENT

RECEIVED

OCT 18 2002

TECH CENTER 1600/2900

AMENDMENT

BOX RCE
Commissioner for Patents
Washington, DC 20231

Dear Sir:

In response to the advisory action mailed September 18, 2002, please amend the above-identified application as follows.

CLEAN COPY OF AMENDED CLAIMS

Please amend the claims as follows.

22. (Twice Amended) A tablet adapted for direct oral administration across the oral mucosa comprising:

a pharmaceutically effective amount of a medicament capable of buccal, sublingual and gingival administration; and

at least one saliva activated effervescent couple present in an amount which is greater than the amount necessary for tablet disintegration and which is sufficient to increase either the rate of the extent of absorption of said medicament across the oral mucosa, and wherein said amount of said at least one effervescent couple is between about 5% by weight and about 80% by weight.

23. (Amended) The tablet of claim 22, wherein said effervescent couple present in an amount between about 20% by weight and about 80% by weight.